Patients in the UK with myelodysplastic syndromes will be celebrating news that the National Institute for Health and Clinical Excellence has been ordered to reassess Celgene’s Vidaza for the National Health Service.
An Appeal Board has agreed with certain objections voiced in appeals by Celgene and a whole host of other bodies - including Royal Colleges and support group MDS UK - against a ruling by the cost watchdog...
Oncology NEWS Today Blog.
By Lois Wingerson | July 7, 2010
Epigenetic cancer therapies–drugs that reverse abnormalities in how DNA is packaged within the nucleus–clearly work for a while against some tumors, and some of these have been approved by FDA. Although they represent an important new class of therapies in hematological malignancies such as myelodysplasia or acute myeloid leukemia, their mechanism of action remains unknown. A number of possible mechanisms of action have...
Celgene's Vidaza to Retain Proprietary Clinical Gold Standard Status for the Treatment of Myelodysplastic Syndromes
TradingMarkets.com
Posted on: Wed, 28 Apr 2010 00:59:22 EDT
Apr 28, 2010 (Close-Up Media via COMTEX)
Decision Resources, a research and advisory firms for pharmaceutical and healthcare issues, finds that Celgene's Vidaza (azacitidine) (seven-day dosing) will retain Decision Resources' proprietary clinical gold standard status through 2013...
Small study had successful results in myelodysplastic syndrome patients
MONDAY, March 29 (HealthDay News) -- The drugs azacitidine and lenalidomide provide a highly effective combination treatment for bone marrow cancer, according to the results of a new study.
The phase 1 study, which was funded by the U.S. National Institutes of Health, included 18 higher-risk patients, median age 68, with myelodysplastic syndromes (MDS). In people with this cancer (which is similar...
